Expert Admissibility in Mass Tort Litigation: the Onglyza Case Study

Expert Admissibility in Mass Tort Litigation: the Onglyza Case Study

• Wednesday, November 2, 2022 12:00 PM - 1:00 PM

AstraZeneca recently obtained federal and state court rulings excluding the causation opinions put forward by hundreds of plaintiffs who claimed that their use of Onglyza and Kombiglyze caused heart failure, ending these high-risk lawsuits. This CLE provides an overview of that litigation, using it to illustrate current standards in expert admissibility cases, and to discuss how pending amendments to Rule 702 would codify the standards applied in the Onglyza litigation.

For additional information on this event, please reach out to ClientCLE@cov.com.